

APPOINTMENT OF LABORATORY LEADER TO THE BOARD

Brian O'Dwyer, CEO of Q² Solutions, joins LBT Board as Non-Executive Director

Adelaide, Australia, 28 September 2021: Australian medical technology company LBT Innovations Limited (ASX: LBT) (LBT or the **Company**), a leader in medical technology automation using artificial intelligence, is pleased to announce the appointment of Brian O'Dwyer to its Board as a Non-Executive Director, commencing 4 October 2021.

Key Points:

- **Brian O'Dwyer joins LBT Board as a Non-Executive Director**
- **CEO of Q² Solutions – Global leader in clinical trials laboratory testing**
- **Over 20 years' experience in the healthcare and laboratory testing industries**

Mr O'Dwyer is based in the United States and has over 20 years' experience leading businesses in the healthcare and laboratory testing industries. Mr O'Dwyer is currently CEO of Q² Solutions, a leading clinical trials laboratory testing organisation and subsidiary of global contract research organisation, IQVIA Inc. Prior to joining IQVIA, Mr O'Dwyer held senior positions at Eurofins Scientific and ICON Plc.

The appointment of Brian O'Dwyer as Non-Executive Director is a significant contribution towards the Company's planned Board rejuvenation process and adds important industry knowledge to the Board that will help inform the Company's ongoing development of its APAS[®] technology.

LBT Chair Elect, Ms Joanne Moss said:

"On behalf of the Board, it is my pleasure to welcome Brian to the Company. Brian brings a wealth of global industry experience and a deep understanding of laboratory testing businesses that will support the Company's future growth as we look to expand the utility of the APAS[®] technology towards new applications."

Incoming Non-Executive Director Mr Brian O'Dwyer said:

"The laboratory testing market is ripe for innovation and in need of automated technologies that deliver real efficiencies to established workflows. The APAS[®] Independence is leading the way in applied AI technology that will drive the next wave of automation. I look forward to being able to share my experiences and help shape the future of this exciting technology."

Mr O'Dwyer holds a bachelor's degree in business studies from Dublin City University, Ireland and is a Certified Management Accountant (The Chartered Institute of Management Accountants).

Approved for release by the LBT Board.

– ENDS –

About LBT Innovations

LBT Innovations (LBT) improves patient outcomes by making healthcare more efficient. Based in Adelaide, South Australia, the Company has a history of developing world leading products in microbiology automation. Its first product, MicroStreak[®], was a global first in the automation of the culture plate streaking process. The Company's second product, the Automated Plate Assessment System (APAS[®]) is being commercialised through LBT's 50% owned joint venture company Clever Culture Systems AG (CCS) with Hettich Holding Beteiligungs- und Verwaltungs-GmbH. Beckman Coulter have also been appointed as Marketing Agent in Europe to assist in facilitating sales. The APAS[®] instrument is based upon LBT's intelligent imaging and machine learning software and remains the only US FDA-cleared artificial intelligence technology for automated imaging, analysis and interpretation of culture plates following incubation.

CONTACTS

LBT Innovations	Investor Enquiries
Brent Barnes Chief Executive Officer & Managing Director Tel: +61 8 8227 1555 E: info@lbtinnovations.com	David Allen / John Granger Hawkesbury Partners Tel: +61 2 9103 9494 E: jgranger@hawkesburypartners.com